We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca has announced that the Phase IV independent TWILIGHT trial, Brilinta (ticagrelor) monotherapy reduced bleeding complications with no increased risk of ischaemic events in patients with diabetes undergoing percutaneous coronary intervention.
It's only been tried so far in guinea pigs, but researchers say a combination of a vaccine and a medicated cream could greatly lower recurrence of genital herpes.